RIGL · NASDAQ
Rigel Pharmaceuticals (RIGL) Stock Price & Fundamentals
Rigel Pharmaceuticals (RIGL) closed at $1,591.28 on Oct 9, 2026, up 0.19% from the previous close of $1,588.31.
Share price, past year
1Y +57.05%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,591.28 |
| Sep 30, 2026 | $1,629.30 |
| Aug 31, 2026 | $1,644.54 |
| Jul 31, 2026 | $1,540.48 |
| Jun 30, 2026 | $1,525.96 |
| May 29, 2026 | $1,412.14 |
| Apr 30, 2026 | $1,396.22 |
| Mar 31, 2026 | $1,349.45 |
| Feb 27, 2026 | $1,317.15 |
| Jan 30, 2026 | $1,320.04 |
| Dec 31, 2025 | $1,201.76 |
| Nov 28, 2025 | $1,153.01 |
| Oct 31, 2025 | $1,074.62 |
Key statistics
- Market cap
- $29.14B
- P/E (TTM)
- 94.2
- EPS (TTM)
- $16.89
- Revenue (TTM)
- $276.79M
- Net income (TTM)
- $321.91M
- Shares outstanding
- 18.3M
- Dividend yield
- —
- 52-week range
- $1,013.22 – $1,697.23
Rigel Pharmaceuticals's market cap is $29.14B, based on a share price of $1,591.28 and 18.3M shares outstanding as of Dec 31, 2025.
Financials
Rigel Pharmaceuticals reported revenue of $294.28M for fiscal 2025, up 64.15% from fiscal 2024.
Rigel Pharmaceuticals earned net income of $367.02M in fiscal 2025, a net margin of 124.7%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $294.28M | +64.2% | $367.02M | 124.7% | $19.48 | — |
| FY2024ended Dec 31, 2024 | $179.28M | +53.4% | $17.49M | 9.8% | $0.99 | — |
| FY2023ended Dec 31, 2023 | $116.88M | −2.8% | −$25.09M | −21.5% | −$1.44 | — |
| FY2022ended Dec 31, 2022 | $120.24M | −19.4% | −$58.57M | −48.7% | −$3.44 | −$74.21M |
| FY2021ended Dec 31, 2021 | $149.24M | +37.4% | −$17.91M | −12.0% | −$1.10 | $5.25M |
| FY2020ended Dec 31, 2020 | $108.62M | +83.2% | −$29.74M | −27.4% | −$1.80 | −$53.45M |
| FY2019ended Dec 31, 2019 | $59.29M | +33.2% | −$66.89M | −112.8% | −$4.00 | −$42.97M |
| FY2018ended Dec 31, 2018 | $44.51M | +892.6% | — | — | −$4.40 | −$59.93M |
| FY2017ended Dec 31, 2017 | $4.48M | −78.0% | — | — | −$6.20 | −$77.72M |
| FY2016ended Dec 31, 2016 | $20.38M | — | — | — | −$7.30 | −$76.69M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $78.70M | $17.29M | $0.88 |
| Q1 FY2026ended Mar 31, 2026 | $58.82M | $8.65M | $0.44 |
| Q4 FY2025ended Dec 31, 2025 | $69.80M | $268.07M | $14.11 |
| Q3 FY2025ended Sep 30, 2025 | $69.46M | $27.90M | $1.46 |
| Q2 FY2025ended Jun 30, 2025 | $101.69M | $59.61M | $3.28 |
| Q1 FY2025ended Mar 31, 2025 | $53.33M | $11.45M | $0.63 |
| Q4 FY2024ended Dec 31, 2024 | $57.60M | $14.34M | $0.82 |
| Q3 FY2024ended Sep 30, 2024 | $55.31M | $12.42M | $0.70 |
Company profile
- Name
- Rigel Pharmaceuticals, Inc.
- Ticker
- RIGL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001034842
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jul 1, 2026
- Jun 17, 2026
- May 20, 2026
- May 12, 2026
- May 5, 2026
- May 5, 2026
Frequently asked questions
What is Rigel Pharmaceuticals's stock price?
Rigel Pharmaceuticals (RIGL) closed at $1,591.28 on Oct 9, 2026, up 0.19% from the previous close of $1,588.31.
What is Rigel Pharmaceuticals's market cap?
Rigel Pharmaceuticals's market cap is $29.14B, based on a share price of $1,591.28 and 18.3M shares outstanding as of Dec 31, 2025.
How much revenue does Rigel Pharmaceuticals make?
Rigel Pharmaceuticals reported revenue of $294.28M for fiscal 2025, up 64.15% from fiscal 2024.
What is RIGL's P/E ratio?
Rigel Pharmaceuticals's price-to-earnings ratio is 94.2, based on trailing twelve-month diluted EPS of $16.89.
Does Rigel Pharmaceuticals pay a dividend?
Rigel Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Rigel Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures